Tirzepatide for Obesity and Sleep Apnea

Benefits of Tirzepatide

The American College of Physicians recommends tirzepatide as a first-line intervention for obstructive sleep apnea (OSA) in overweight and obese patients, producing substantial weight reduction, which is strongly recommended for OSA treatment 1, 2, 3
The American Thoracic Society suggests that tirzepatide can be effective for patients with obesity and moderate-to-severe OSA, reducing the apnea-hypopnea index (AHI) and improving sleep quality 2

The British Pharmacological Society reports that the most common adverse effects of tirzepatide are gastrointestinal in nature, including nausea 4, vomiting 5, diarrhea 2, and abdominal discomfort
The American Heart Association notes that tirzepatide requires ongoing use to maintain benefits, with potential weight regain if discontinued, and may cause dry mouth and taste disturbances (dysgeusia) 2, 5

The American College of Cardiology recommends considering tirzepatide for patients with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with OSA who have not achieved sufficient weight loss through lifestyle modifications alone 2, 6
The American Diabetes Association suggests that tirzepatide can be used as an adjunct to CPAP therapy in patients who remain symptomatic or have poor CPAP adherence, and for patients who cannot tolerate or refuse CPAP therapy 7
The European Society of Cardiology notes that tirzepatide may be beneficial for patients with multiple comorbidities associated with obesity, such as type 2 diabetes, hypertension, or cardiovascular disease 6, 8

The American College of Physicians recommends a first-line approach of comprehensive lifestyle intervention for weight loss, and considering adding tirzepatide if there is an inadequate response to lifestyle intervention 1, 3, 2, 6

The American Heart Association advises avoiding tirzepatide in patients with active cardiovascular disease, and using caution in patients taking medications that may interact with tirzepatide or affect sleep apnea independently 2, 4

The American Thoracic Society recommends regular assessment of weight and BMI, and follow-up sleep studies to evaluate improvements in AHI and oxygen saturation 3

Obesity‑related pharyngeal fat deposition increases upper‑airway critical closing pressure (Pcrit), promoting airway collapse during sleep. This pathophysiological link was described in respiratory research studies. 9
Weight loss induced by tirzepatide reduces pharyngeal fat stores and improves airway mechanics, directly counteracting the obesity‑driven increase in Pcrit. Evidence comes from clinical investigations of tirzepatide’s effects on upper‑airway anatomy. 10

The American Thoracic Society issues a strong recommendation that weight loss be used as first‑line therapy for all overweight/obese patients with OSA (BMI ≥ 25 kg/m²). Tirzepatide is presented as a pharmacologic option when lifestyle measures are insufficient. (Strong recommendation, high‑quality evidence). 10

Tirzepatide therapy leads to measurable improvements in sleep architecture, with REM sleep increasing by approximately 1–10 % and deep (slow‑wave) sleep rising up to 17 %. These changes were reported in a European Respiratory Journal cohort of OSA patients receiving tirzepatide. (Observational data). 11